FDA Inspection
Genentech, Inc.Genentech, Inc. – FDA Inspection, May 2, 2024
Record Details
This FDA Inspection record concerns Genentech, Inc., with an inspection on May 2, 2024, issued by the Center for Drug Evaluation and Research.
- Company
- Genentech, Inc.
- Inspection Date
- May 2, 2024
- People
- Dustin R. Abaonza (Company Rep)
- Sheilyn H. Huang (Issuing Officer)
View Company Profile
ID · d7fa8583-d22f-424b-8e09-2c1404f53842
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1236964
- FDA center
- Human Drugs
- Project area
- Postmarket Surv. and Epidemiology
FDA Citations
2- Failure to comply with REMS Implementation System
- FDCA 505-1(f)(4)Failure to comply with REMS Implementation System
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Genentech, Inc.
34| Date | Classification | Office | Project area |
|---|---|---|---|
| August 4, 2026 | Not classified | San Francisco District Office | |
| May 15, 2026 | Not classified | San Francisco District Office | |
| April 7, 2026 | Not classified | San Francisco District Office | |
| April 21, 2025 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
| March 20, 2024 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Genentech, Inc.
- FDA Inspection 1332732 - 2026-08-04
- FDA Inspection 1322404 - 2026-05-15
- FDA Inspection 1314654 - 2026-04-07
- FDA Inspection 1263573 - 2025-04-21
- FDA Inspection 1235655 - 2024-03-20
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.